Skip to main content

Table 4 Cox regression analysis

From: Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register

Variables

Hazard ratio (CI95%)

p

Age (ref. adults)

 Young

0.92 (0.60–1.40)

0.692

 Elderly

1.21 (0.97–1.52)

0.089

 Very Elderly

1.50 (1.01–2.24)

0.046

Female gender

1.42 (1.22–1.64)

< 0.001

Diagnosis (ref. RA)

 AS

0.93 (0.76–1.12)

0.432

 PsA

0.96 (0.81–1.14)

0.668

Comorbidities

 Charlson index

1.13 (1.06–1.21)

< 0.001

 Smoking (ref. No)

  Smoker/past smoker

1.16 (0.99–1.35)

0.059

Treatments

 Corticosteroids

1.04 (0.85–1.27)

0.699

 Corticosteroid dose

0.99 (0.97–1.00)

0.140

 MTX

1.21 (1.05–1.39)

0.008

 Other DMARDs

1.10 (0.95–1.28)

0.182

Disease duration

1.01 (1.00–1.02)

0.007

  1. AS ankylosing spondylitis, CI95% confidence interval 95%, DMARDs disease-modifying antirheumatic drugs, HR hazard ratios, MTX Methotrexate, PsA psoriatic arthritis, RA rheumatoid arthritis
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us